AF
VRTX icon

Avanza Fonder’s Vertex Pharmaceuticals VRTX Stock Holding History

Avanza Fonder’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14M Buy
28,198
+551
+2% +$244K 0.3% 60
2026
Q1 		$12.3M Buy
27,647
+62
+0.2% +$28.9K 0.34% 58
2025
Q4 		$12.5M Buy
27,585
+532
+2% +$229K 0.32% 59
2025
Q3 		$10.6M Buy
27,053
+1,628
+6% +$680K 0.27% 64
2025
Q2 		$11.3M Buy
25,425
+1,405
+6% +$647K 0.34% 52
2025
Q1 		$11.6M Sell
24,020
-4,138
-15% -$1.93M 0.38% 47
2024
Q4 		$11.3M Buy
+28,158
New +$13.1M 0.34% 53

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return

Avanza Fonder's VRTX Position: Q2 2026 in Review

Avanza Fonder increased its Vertex Pharmaceuticals (VRTX) stake by 2% in Q2 2026, buying an estimated $244K and bringing the position to 28,198 shares worth $14M. The position accounts for 0.3% of the portfolio, ranked #60.

Avanza Fonder first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. 256 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Avanza Fonder held 28,198 shares of Vertex Pharmaceuticals worth $14M as of Q2 2026.
  • Avanza Fonder bought 551 Vertex Pharmaceuticals shares in Q2 2026, an estimated $244K.
  • Vertex Pharmaceuticals made up 0.3% of Avanza Fonder's portfolio in Q2 2026, its #60 holding.
  • Avanza Fonder first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 256 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Avanza Fonder's 13F filing for Q2 2026, filed 17 Jul 2026.